Quizar 17.7 Mg (Quizartinib) Tablets

Introduction

Quizar 17.7 mg (Quizartinib) is a potent, second-generation, highly selective tyrosine kinase inhibitor (TKI). Manufactured by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, this medication is a breakthrough in the treatment of Acute Myeloid Leukemia (AML). Specifically engineered to target the FLT3-ITD mutation, Quizar acts as a precision therapy that blocks the signals causing the rapid, uncontrolled growth of leukemic cells, offering a more targeted approach than traditional non-selective therapies.

Indications

Quizar 17.7 mg (Quizartinib) is indicated for:

Newly Diagnosed FLT3-ITD+ AML: In combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy in adult patients.
Maintenance Therapy: As a single-agent maintenance therapy following consolidation chemotherapy for patients with confirmed FLT3-ITD positive AML.
Requirement: Clinical use must be preceded by a validated diagnostic test confirming the presence of the FLT3 internal tandem duplication (ITD) mutation.

Pharmacology

Quizartinib, the active ingredient in Quizar, is a Type II FLT3 inhibitor.

Mechanism: It selectively binds to the inactive conformation of the FLT3 receptor. By inhibiting the Fms-like tyrosine kinase 3, it prevents autophosphorylation and shuts down downstream signaling pathways (including STAT5 and MAPK).
Effect: This disruption leads to the cessation of leukemic cell proliferation and induces apoptosis (programmed cell death) in cells harboring the FLT3-ITD mutation. Its high selectivity for FLT3-ITD over other kinases reduces the likelihood of off-target toxicities.

Dosage & Administration

Oral Administration for Adults:

Induction/Consolidation Phases: Administered on specific days of the 28-day chemotherapy cycle (e.g., Days 8–21 for induction).
Maintenance Phase: Typically starts at 26.5 mg once daily, with potential escalation to 53 mg based on patient tolerance.
Administration: Tablets must be swallowed whole with water. They can be taken with or without food at the same time each day.
Missed Dose: If a dose is missed, take it as soon as possible on the same day. Do not double the dose the next day.

Drug Interactions

Strong CYP3A Inhibitors: (e.g., Clarithromycin, Itraconazole) May increase Quizartinib levels; dose reduction is necessary.
Strong CYP3A Inducers: (e.g., Carbamazepine, Rifampin) May significantly reduce drug effectiveness; avoid co-administration.
QT-Prolonging Agents: Use with extreme caution alongside other drugs that prolong the QT interval (e.g., certain antibiotics or anti-arrhythmics).

Contraindications

Cardiac Conditions: Patients with a history of long QT syndrome, severe ventricular arrhythmias, or recent myocardial infarction.
Electrolyte Imbalance: Hypokalemia or hypomagnesemia must be corrected before starting treatment.
Hypersensitivity: Known allergy to Quizartinib or any components of the tablet.

Side Effects

Patients receiving Quizar 17.7 mg may experience:

Cardiac: QT interval prolongation (monitored via ECG).
Hematological: Febrile neutropenia, thrombocytopenia, and anemia.
Gastrointestinal: Nausea, diarrhea, abdominal pain, and mucositis (mouth sores).
General: Fatigue, headache, and peripheral edema.

Pregnancy & Lactation

Pregnancy: Quizartinib can cause severe fetal harm. Females should use effective non-hormonal contraception during and for 7 months after treatment.
Lactation: Do not breastfeed while on Quizar and for at least one month after the final dose.

Precautions & Warnings

QT Prolongation: Quizartinib carries a risk of life-threatening arrhythmias. Regular ECG monitoring is mandatory, typically weekly during early phases.
Hepatotoxicity: Periodic liver function tests (LFTs) are required to monitor for potential drug-induced liver injury.
Infection Risk: Patients should be monitored closely for signs of severe infection due to potential neutropenia.

Use in Special Populations

Pediatric Use: Safety and effectiveness have not been established in patients under 18 years of age.
Hepatic/Renal Impairment: No dose adjustment is generally required for mild to moderate impairment; use with caution in severe cases.

Overdose Effects

Overdose may lead to severe QT prolongation or cardiac complications. Management involves immediate ECG monitoring and hospitalization for supportive care.

Storage

Condition: Store at room temperature (15°C to 30°C).
Environment: Keep in the original moisture-resistant container. Protect from direct heat and light. Keep out of reach of children.

Supplier Information

Orio Pharma is a premium supplier of specialized oncology medicines. We are committed to providing reliable, global access to the latest cancer therapies. Our logistics network ensures that life-saving treatments like Quizar 17.7 mg reach patients safely and efficiently. For international supply queries, please contact our distribution center.

Manufacturer Information

Quizar 17.7 mg is manufactured by Everest Pharmaceuticals Ltd., a leading manufacturer in Bangladesh recognized for its high-standard facilities and expertise in producing advanced, targeted generic oncology medications.